Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Moleculin Biotech (MBRX) Income from Continuing Operations (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Income from Continuing Operations data on record, last reported at 5866000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 16.59% year-over-year to 5866000.0; the TTM value through Sep 2025 reached 24069000.0, up 14.5%, while the annual FY2024 figure was 26091000.0, 7.68% up from the prior year.
  • Income from Continuing Operations reached 5866000.0 in Q3 2025 per MBRX's latest filing, down from 5694000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5206000.0 in Q4 2021 and bottomed at 9050000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 6589263.16, with a median of 6157000.0 recorded in 2021.
  • Peak YoY movement for Income from Continuing Operations: tumbled 81.35% in 2021, then soared 37.86% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 5206000.0 in 2021, then crashed by 32.96% to 6922000.0 in 2022, then dropped by 25.07% to 8657000.0 in 2023, then rose by 23.81% to 6596000.0 in 2024, then grew by 11.07% to 5866000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 5866000.0 in Q3 2025, 5694000.0 in Q2 2025, and 5913000.0 in Q1 2025.